Zealand Pharma Initiates DKK 1.3B Share Buy-Back
Analysis based on 8 articles · First reported May 07, 2026 · Last updated May 07, 2026
The initiation of Zealand Pharma's DKK 1.3 billion share buy-back program is likely to be viewed positively by the market, potentially boosting investor confidence and the company's stock price. This action, coupled with expected significant milestone payments from Roche, signals strong financial health and a commitment to shareholder returns, which could attract further investment in Zealand Pharma and the biotechnology sector.
Zealand Pharma has announced the initiation of a DKK 1.3 billion (USD 200 million) share buy-back program, effective from May 7, 2026, to October 31, 2026. The program, managed by Danske Bank, aims to meet obligations from share-based incentive programs and reduce share capital. This decision is underpinned by Zealand Pharma's robust cash position of USD 2.3 billion and anticipated milestone payments of USD 700 million from Roche in 2026, including USD 575 million for the initiation of Phase 3 trials for petrelintide monotherapy. The company emphasizes its financial strength to invest in research and development for metabolic health while returning capital to shareholders.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard